Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice

Prostate

Volumn 48, Issue 1, 2001, Pages 47-53

  Smith, Peter C ^a   Keller, Evan T ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antibody; Chemotherapy; Cytokine; Interleukin 6; Prostate cancer

Indexed keywords

ETOPOSIDE; IMMUNOGLOBULIN G; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER RESISTANCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0035875931     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1080     Document Type: Article

References (28)

1. Cancer statistics, 1999
2. Management of relapsing disease in prostate cancer
3. Molecular and cellular biology of interleukin-6 and its receptor
4. Interleukin-6 and prostate cancer progression
5. Interleukin-6: A candidate mediator of human prostate cancer morbidity
6. Characterization of the role of IL-6 in the progression of prostate cancer
7. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines
8. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity
9. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants
10. Orchiectomy increases bone marrow interleukin-6 levels in mice
11. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance
12. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice
13. Inhibition of prostate cancer growth by estramustine and etoposide: Evidence for interaction at the nuclear matrix
14. Construction and functional analysis of hybrid interleukin-6 variants. Characterization of the role of C-terminus for species specificity
15. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis
16. Inhibition of NFkappaB activity through maintenance of IkBa levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter
17. Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients
18. Elevated levels of circulating interleukin-6 and transforming growth factor-betal in patients with metastatic prostatic carcinoma
19. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways
20. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
21. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
22. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma
23. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study
24. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: Antitumor activity in xenograft model of multiple myeloma
25. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line
26. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo
27. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines
28. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue